万拉法新与多虑平治疗焦虑症对照研究
万拉法新；多虑平；焦虑症,,万拉法新；多虑平；焦虑症,【摘要】,【关键词】,1对象和方法,2结果,3讨论,参考文献
【摘要】 目的 比较万拉法新与多虑平治疗焦虑症的疗效与副反应。 方法 将68例符合CCMD-3诊断标准的焦虑症患者，随机分为万拉法新治疗(A)组34例，多虑平治疗(B)组34例，共治疗6w。于治疗前及治疗第2、4、6w末，采用HAMA、SAS和TESS评价临床疗效与副反应。结果 万拉法新组治疗1w后HAMA、SAS评分与治疗前比较有非常显著性差异(P<0.01；多虑平组治疗2w后HAMA、SAS评分与治疗前比较有非常显著性差异(P<0.01；两组间比较除第1w末有显著性差异(P<0.05外，2、4、6w末差异无显著性(P>0.05)；万拉法新组副反应明显少于多虑平组，两组比较差异有显著性(P<0.01)。 结论 万拉法新治疗焦虑症安全、有效。【关键词】 万拉法新；多虑平；焦虑症
A controlled study between venlafaxine and doxepin in the treatment of anxiety
Bai Zhaoqing, Xi Hailong
(Nanyang mental hospital,Nanyang 473008, Henan, China)
【Abstract】 Objective To compare the efficacy and side effects between venlafaxine and doxepin in the treatment of anxiety. Methods 68 patients with anxiety(met the criterion of CCMD3 for anxiety) were randomly divided into group A(n=34,venlafaxine) and B(n=34,doxepin) for 6 weeks, efficacy and side effects assessed by HAMA,SAS and TESS before and at the ends of 2nd,4th and 6th week during treatment. Results After one week treatment, scores of HAMA and SAS showed significant difference from pre-treatment(P<0.01) in group A; after two week treatment, scores of HAMA and SAS showed significant difference from pretreatment(P<0.01) in group B; comparison of the 2 groups showed significant difference at end of 1st week(P<0.01) and no significant difference at ends of 2nd,4th and 6th week(P>0.05);side effects of group A were fewer than that of group B, comparison of the 2 groups showed significant difference(P<0.01). Conclusion Venlafaxine is safe and effective in the treatment of anxiety. ......
您现在查看是摘要页，全文长 5150 字符。